FDA’s National Center for Toxicological Research is latest site of SOMAscan assay


SomaLogic announced today that the U.S. Food and Drug Administration’s (FDA) National Center for Toxicological Research (NCTR) has reached an agreement with SomaLogic to deploy the SOMAscan proteomics assay in the NCTR’s research laboratories in Jefferson, Ark. It is expected that the assay will be installed and fully functional at NCTR by early 2016.

Founded in 1971, NCTR’s mission is to “develop and support innovative tools and evaluation of approaches that FDA uses to protect and promote individual and public health.” More than 500 scientists work at NCTR, which also hosts students, postdoctoral fellows, visiting scientists and FDA staff who go to NCTR to learn new laboratory technologies.

“We are delighted to partner with the FDA’s National Center for Toxicology Research to give its extensive network of researchers access to the SOMAscan assay,” said Byron Hewett, Chief Executive Officer of SomaLogic. “The deployment of this cutting-edge proteomics tool in the NCTR laboratories will contribute greatly to their efforts to fufill their important national mission.”

Compared to other current proteomic technologies, SomaLogic’s platform offers unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,310 different SOMAmer reagents, can efficiently, accurately and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.

The FDA’s NCTR is the ninth leading research center announced to date that has brought the SOMAscan assay “in house” to accelerate its scientific efforts. SomaLogic is continuing to expand research access to the SOMAscan assay through placements at additional centers over the next several months.